PainReform Ltd. (PRFX): Price and Financial Metrics
GET POWR RATINGS... FREE!
PRFX Stock Price Chart Interactive Chart >
PRFX Price/Volume Stats
| Current price | $0.69 | 52-week high | $1.49 |
| Prev. close | $0.64 | 52-week low | $0.34 |
| Day low | $0.66 | Volume | 37,300 |
| Day high | $0.70 | Avg. volume | 292,775 |
| 50-day MA | $0.57 | Dividend yield | N/A |
| 200-day MA | $0.64 | Market Cap | 7.34M |
PainReform Ltd. (PRFX) Company Bio
PainReform Ltd. operates as a pharmaceutical company. It develops and markets pharmaceuticals. The firm focuses on developing reformulation of pain therapeutics, PainReform applies its propriety formulation technologies to prolong and enhance efficacy, reduce adverse effects shortening recovery time and reduce the need of augmentation with drugs such as opioids and NSAIDS. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.
Latest PRFX News From Around the Web
Below are the latest news stories about PAINREFORM LTD that investors may wish to consider to help them evaluate PRFX as an investment opportunity.
PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy SurgeryFirst 15 patients administered PRF-110 intra-operativelyTEL AVIV, Israel, March 28, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced completion of treatment for the first part, of its two-part Phase 3 clinical trial of PRF-110, in which 15 patients were enrolled and administered PRF-110 intra-operatively to review surgeon’s handling o |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning! |
PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in BunionectomyTEL AVIV, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the year ended December 31, 2022. Ilan Hadar, Chief Executive Officer, stated, “We are pleased to report a number of important milestones this past year which have helped advance the clinical development of PRF-110, our lead drug candidat |
PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy SurgeryInitial pharmacokinetic data on first 15 patients expected in May 2023TEL AVIV, Israel, March 14, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has commenced a Phase 3 clinical trial of PRF-110, the Company’s lead drug candidate, targeting the post-operative extended pain relief market. The Phase 3 trial is a randomized, do |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're starting off Friday with an overview of the biggest pre-market stock movers traders will want to keep an eye on today! |
PRFX Price Returns
| 1-mo | 24.08% |
| 3-mo | 67.19% |
| 6-mo | 6.15% |
| 1-year | -41.77% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 67.19% |
| 2022 | -68.97% |
| 2021 | -70.25% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...